CERO THERAPEUTICS HOLDINGS, INC.
No enriched coverage for $CERO in the last 7 days.
No SEC Form 4 filings for $CERO in the last 30 days.
See all $CERO insider activity →SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers The Debt investment is expected to accelerate development of CERo’s lead t
CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), completed a secured financing transaction with SRX Global Inc. (formerly known as SRx Health Solutions, Inc.) (“SRX”). In connection
CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029846301ex4-1.htm SECOND AMENDED AND RESTATED NOTE (JULY 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE R
Recent CERO coverage spans financial news and corporate actions.
New funding could accelerate CER-1236 trials and improve CERo's valuation.
The financing provides immediate capital but adds debt and covenants, likely pressuring the share price in the short term.
The filing signals near-term dilution risk and financing overhang via a lender option to convert principal and accrued interest into CERO common stock.
The filing discloses a new/updated dilutive financing structure (convertible note with a floor price), which can pressure equity via conversion over time.
The appointment of Eric Francois, a biotech finance veteran, to CERo Therapeutics' board signals strengthened strategic leadership, potentially accelerating clinical development and capital initiatives.
AlphAI scores every news story that mentions CERO with an AI model for sentiment and relevance, and aggregates insider trades from CERO THERAPEUTICS HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers The Debt investment is expected to accelerate development of CERo’s lead t
2 min readCERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), completed a secured financing transaction with SRX Global Inc. (formerly known as SRx Health Solutions, Inc.) (“SRX”). In connection
1 min readCERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029846301ex4-1.htm SECOND AMENDED AND RESTATED NOTE (JULY 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE R
3 min readCERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029602201ex4-1.htm AMENDED AND RESTATED NOTE (JUNE 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRA
4 min readCERo Therapeutics (OTCQB: CERO) has appointed Eric Francois, a biotechnology finance veteran with over 25 years of experience, to its Board of Directors. Francois previously served as CFO of SCYNEXIS, where he raised over $300 million, and also held senior banking positions. His expertise in capital raising, M&A, and business development is expected to significantly contribute to CERo's cellular immunotherapy programs and ongoing human clinical trials for cancer treatment.
2 min readU.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.03% to 47,644.08 while the NASDAQ fell 1.13% to 23,687.37. The S&P 500 also fell, dropping, 0.63% to 6,847.40.
4 min readTrading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October ...
3 min readCompany completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance ...
3 min readStudy's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval ...
2 min readThird patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort ...
3 min read
